[Email id of designated official for the purpose of grievance redressal]
Unaudited Financial Results for the Quarter ended 30th June, 2006 |
|||
---|---|---|---|
(Rs. in Lacs) |
|||
PARTICULARS |
Quarter ended 30.06.2006 (Unaudited) |
Quarter ended 30.06.2005 (Reviewed) |
Year Ended 31.03.2006 (Unaudited) |
INCOME FROM OPERATIONS | 8342.84 | 7053.16 | 28487.05 |
OTHER INCOME | 11.61 | 10.74 | 142.04 |
TOTAL INCOME | 8354.45 | 7063.90 | 28629.09 |
TOTAL EXPENDITURE | 7291.72 | 6276.10 | 25426.26 |
DECREASE IN STOCK IN TRADE | 232.16 | 281.13 | 190.32 |
CONSUMPTION OF RAW MATERIAL | 5885.28 | 5063.96 | 21666.59 |
COST OF SALES | 4372.44 | 3706.53 | 16166.43 |
STAFF COST | 287.77 | 226.17 | 933.65 |
OTHER EXPENSES | 886.51 | 704.84 | 3016.34 |
INTEREST | 331.84 | 198.62 | 956.56 |
DEPRECIATION | 68.15 | 32.71 | 140.30 |
PROFIT BEFORE TAX | 662.74 | 556.47 | 2105.97 |
PROVISION FOR TAX | 74.36 | 41.74 | 160.14 |
PROVISION FOR DEFERRED TAX | 52.15 | 2.50 | 182.09 |
NET PROFIT | 536.23 | 512.23 | 1763.74 |
PAID UP EQUITY SHARE CAPITAL(FACE VALUE OF RS 2/- PER SHARE) | 743.57 | 727.57 | 743.57 |
RESERVES EXCLUDING REVALUATION RESERVES | |||
E.P.S. Rs. NOT ANNUALISED( FACE VALUE OF RS 2/- PER SHARE) | 1.44 | 1.41 | 4.74 |
AGGREGATE OF NON-PROMOTERS SHAREHOLDING | |||
NUMBER OF SHARES | 24056475 | 23791475 | 24056475 |
% OF SHARE HOLDING | 64.71 | 65.40 | 64.71 |
Notes:- |
|||
1. Income from Operation rose by 18.28% and Net Profit by 4.68% as compared to corresponding quarter of the previous year. 2. The above results were reviewed by the audit committee and taken on record by the Board of Directors at its meeting held on 29.07.2006. 3.During the quarter Company's new finished dosage facility at baddi to manufacture Tablets, Injectibles and Liquids was put to operation. The Company was also laid the foundation stone for the putting up another new facility for cephalosporins and soft gelatin capsules in Baddi. 4. The Company had recieved 06 complaints during the quarter under review which were duly redressed to the satisfaction of the shareholders during the same quarter and as such,there were no pending complains as on 30th June 2006. 5.The Company is exclusively in the Pharmaceutical business segment. 6. Previous Year Figures have been re-grouped and/or re-arranged wherever considered necessary. |
|||
By Order of the Board |
|||
Dated: 29.07.2006 | (Dr. Gopal Munjal) |
||
Place: Chandigarh | Chairman |
||